Moderna, Inc. (NASDAQ:MRNA - Get Free Report) saw unusually large options trading on Friday. Stock investors bought 133,074 call options on the stock. Thisrepresentsanincreaseof61% compared to the average daily volume of 82,472 call options.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on MRNA. Barclays restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Citigroup started coverage on Moderna in a research report on Friday. They set a "neutral" rating and a $40.00 target price on the stock. William Blair restated a "market perform" rating on shares of Moderna in a research report on Monday, June 2nd. Royal Bank Of Canada dropped their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Finally, JPMorgan Chase & Co. set a $26.00 target price on Moderna in a report on Friday. Four analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $46.11.
Check Out Our Latest Report on MRNA
Moderna Trading Down 8.2%
Moderna stock traded down $2.42 during trading on Friday, reaching $27.14. The company had a trading volume of 12,340,990 shares, compared to its average volume of 10,936,340. Moderna has a 52 week low of $23.15 and a 52 week high of $91.99. The firm's 50-day simple moving average is $29.20 and its 200 day simple moving average is $30.34. The firm has a market capitalization of $10.50 billion, a price-to-earnings ratio of -3.11 and a beta of 1.84.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.86. The company had revenue of $142.00 million for the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. Moderna's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same period last year, the firm earned ($3.33) EPS. On average, analysts predict that Moderna will post -9.61 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of MRNA. Teacher Retirement System of Texas raised its stake in Moderna by 4.7% in the second quarter. Teacher Retirement System of Texas now owns 93,662 shares of the company's stock worth $2,584,000 after buying an additional 4,166 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Moderna during the second quarter valued at $2,836,000. OVERSEA CHINESE BANKING Corp Ltd boosted its holdings in Moderna by 20.8% in the second quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 49,241 shares of the company's stock valued at $1,356,000 after purchasing an additional 8,469 shares during the last quarter. Green Alpha Advisors LLC boosted its holdings in Moderna by 9.1% in the second quarter. Green Alpha Advisors LLC now owns 31,271 shares of the company's stock valued at $863,000 after purchasing an additional 2,597 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D boosted its holdings in Moderna by 3.9% in the second quarter. State of New Jersey Common Pension Fund D now owns 119,338 shares of the company's stock valued at $3,293,000 after purchasing an additional 4,516 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.
About Moderna
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.